Drugs / NY-ESO-1.A2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00145158 | Jan 2005 → Nov 2007 | melanoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1.A2 | “These peptides are the following: MAGE-1.A2, MAGE-3.A2, MAGE-4.A2, MAGE-10.A2, MAGE-C2.A2 (ALKD), and NA17.A2 (20% intradermally and 80% subcutaneously); NY-ESO-1.A2 and...” NCT00145158 ↗ |
| Route | Subcutaneous | “NY-ESO-1.A2 and Tyrosinase.A2 (100% subcutaneously)” NCT00145158 ↗ |